IPSS-M Scoring System in Myelodysplastic Syndrome

In this article

What the IPSS-M Is and Who Uses It

The Molecular International Prognostic Scoring System (IPSS-M) is a risk calculator for myelodysplastic syndrome (MDS). It combines three kinds of information: routine blood and bone marrow results, chromosome findings, and mutations in 31 genes [1]. The result is a single score that places each patient in one of six risk categories, from very low to very high. The International Working Group for Prognosis in MDS published it in 2022. It was built from 2,957 patients and tested in an independent group of 754 patients [1]. This genetic focus directly aligns with the 2022 World Health Organization (WHO) and International Consensus Classification (ICC) guidelines, which now define several MDS subtypes primarily by their molecular drivers [5,6].

The IPSS-M is used to estimate three outcomes: overall survival, leukemia-free survival, and the chance that the disease turns into acute myeloid leukemia (AML) [1]. Those estimates guide treatment choices. They help decide whether a patient needs supportive care or stronger therapy, and when to start planning a stem cell transplant [4]. Hematologists and oncologists calculate the score using results from the pathology and molecular laboratory. It also helps researchers decide who can join clinical trials. The older IPSS-R remains in use where gene sequencing is not available [2,3].

How the Score Is Built

Three groups of data feed the IPSS-M:

  • Clinical values: hemoglobin, platelet count, and the percentage of blasts (immature cells) in the bone marrow. The absolute neutrophil count (ANC), which is a core pillar of the older IPSS-R, was removed because statistical modeling proved it lost its independent prognostic value once molecular data was included [1]. Additionally, while patient age is not part of the core disease score, the online IPSS-M calculator uses age to adjust and generate individualized overall survival probabilities [1].
  • Chromosome findings: the five IPSS-R cytogenetic groups, from very good to very poor.
  • Gene mutations: the presence of mutations in 31 genes, with special attention to TP53 and SF3B1. A TP53 mutation with both gene copies damaged (multi-hit), defined clinically as having multiple TP53 mutations, one mutation concurrent with a chromosomal deletion (loss of heterozygosity), or a single mutation with a variant allele frequency over 50%, is the most heavily weighted adverse variable in the algorithm [1]. On the other hand, an isolated SF3B1 mutation lowers the risk score, but this protective effect is canceled if high-risk concurrent mutations (such as RUNX1, EZH2, or ASXL1) are also present [1].

If a gene result is missing, the calculator reports a best-case and a worst-case score, so the category can still be estimated [1].

IPSS-M Calculator

IPSS-M Risk Calculator (Educational Demo)

⚠️ Educational Purposes Only: This is a simplified interactive tool designed to illustrate the case studies in this article. It does not contain the full 31-gene regression algorithm. For actual patient care, clinicians must use the official IPSS-M web calculator.

Interpreting the Result

The IPSS-M gives a continuous number. A higher number means higher risk, and negative values indicate lower risk. The number then maps onto six categories. The survival figures below are median values from the original study cohort [1].

IPSS-M Results Interpretation
CategoryScore rangeMedian overall survival
Very Low−1.5 or lower
About 10.6 years
Low−1.5 to −0.5
About 6.0 years
Moderate Low−0.5 to 0
About 4.6 years
Moderate High0 to 0.5
About 2.8 years
High0.5 to 1.5
About 1.7 years
Very HighAbove 1.5
About 1.0 year

We often group these into two practical tiers. Very Low, Low, and Moderate Low are treated as lower-risk disease. The goal there is to improve blood counts, reduce transfusions, and protect quality of life. Moderate High, High, and Very High are treated as higher-risk disease. The goal there is to slow progression to AML and, for fit patients, to reach a cure with allogeneic stem cell transplantation [4].

Three cautions apply when reading a result:

  • These are group medians, not predictions for one person. Age, other illnesses, and response to treatment all change the outlook.
  • The IPSS-M changes the category for many patients. In the original cohort, about 46% moved to a different group compared with the IPSS-R [1]. Later validation studies reported a similar pattern [2].
  • The score supports a clinical decision. It does not replace one.

Case Scenarios

These are illustrative composites, not real patients. Exact categories depend on the full calculation.

Case 1: A mutation that lowers the risk.

A 68-year-old woman presents with tiredness. Her lab results show a hemoglobin of 9.5 g/dL, platelet count of 250 × 10⁹/L, 2% bone marrow blasts, and a normal karyotype. Molecular sequencing finds an SF3B1 mutation with no other high-risk concurrent mutations.

Calculator Exercise: What is her estimated IPSS-M risk category?

Clinical Interpretation: Clinical inputs (low blast count, normal platelets, good cytogenetics) + isolated SF3B1 mutation (which applies a negative mathematical weight to lower the score) = IPSS-M Category: Low Risk. She is treated for lower-risk disease with an erythropoiesis-stimulating agent or luspatercept to manage her anemia. A stem cell transplant is not considered at this time.


Case 2: A hidden mutation that raises the risk.

A 58-year-old man presents with normal blood counts, 0% bone marrow blasts, and normal cytogenetics. This profile previously placed him in the "Low" risk group under the older IPSS-R system. However, his next-generation sequencing (NGS) panel reveals a multi-hit TP53 mutation.

Calculator Exercise: What is his estimated IPSS-M risk category?

Clinical Interpretation: Clinical inputs (normal counts, no blasts, good cytogenetics) + multi-hit TP53 (the most heavily weighted adverse variable in the algorithm) = IPSS-M Category: High Risk. Because the IPSS-M actively re-stratifies him into a higher-risk tier, his team starts stem cell transplant planning early and discusses clinical trials, as standard therapy alone is unlikely to control this subtype.


Case 3: Moderate risk and a treatment decision.

A 74-year-old man undergoes evaluation for moderate cytopenias. His bone marrow biopsy reveals 8% blasts and normal cytogenetics. Molecular testing identifies mutations in both ASXL1 and RUNX1.

Calculator Exercise: What is his estimated IPSS-M risk category?

Clinical Interpretation: Clinical inputs (8% blasts, which adds intermediate risk) + ASXL1 and RUNX1 (both "main effect" genes that carry distinct positive weights) = IPSS-M Category: Moderate-High Risk. Because the score places him in a higher-risk tier and he is physically fit, the care team considers active intervention with a hypomethylating agent (such as azacitidine) and refers him to a transplant center to determine his eligibility.

Limitations of the Scoring System

While the IPSS-M is currently the most precise prognostic tool for MDS, it has several important clinical and practical limitations:

  • Reliance on Next-Generation Sequencing (NGS): The most significant barrier is access. The IPSS-M requires a 31-gene NGS panel, which is expensive, resource-intensive, and often unavailable in community oncology practices or developing countries. For centers without molecular testing, the older IPSS-R remains the standard.
  • Testing Turnaround Time: NGS panels typically take two to four weeks to process. For patients with aggressive or rapidly progressing disease, clinicians may need to make initial treatment decisions before the IPSS-M score is available.
  • Exclusion of Comorbidities and Frailty: While the web calculator adjusts survival estimates based on age, the IPSS-M algorithm does not account for the patient's performance status, organ function, or other medical conditions. A patient with a "Moderate-Low" risk score but severe heart failure will have a vastly different clinical trajectory than a fit patient with the same score.
  • Snapshot in Time (Clonal Evolution): The IPSS-M is typically calculated at the time of diagnosis. However,MDS is a dynamic disease. A patient's mutational profile can change over time (clonal evolution), meaning the baseline score may not accurately reflect the disease's risk profile months or years later.
  • Treatment-Naive Bias: The model was built and validated primarily using data from patients at the time of diagnosis prior to disease-modifying treatments. Its accuracy in predicting survival or AML transformation after a patient has already received therapies (like hypomethylating agents) is less certain.
  • Missing Gene Data: If a laboratory uses a smaller NGS panel that misses some of the 31 required genes, the calculator has to output a "best-case" and "worst-case" score range rather than a single definitive category, which can introduce clinical ambiguity.

Disclaimer: This article is intended for educational and informational purposes only. It is not intended to be a substitute for informed professional medical advice, diagnosis, or treatment. While the information presented here is derived from credible medical sources and is believed to be accurate and up-to-date, it is not guaranteed to be complete or error-free. See additional information.

References

  1. Bernard, E., Tuechler, H., Greenberg, P. L., Hasserjian, R. P., Arango Ossa, J. E., Nannya, Y., Devlin, S. M., Creignou, M., Pinel, P., Monnier, L., Gundem, G., Medina-Martinez, J. S., Domenico, D., Jädersten, M., Germing, U., Sanz, G., van de Loosdrecht, A. A., Kosmider, O., Follo, M. Y., Thol, F., … Papaemmanuil, E. (2022). Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. NEJM evidence, 1(7), EVIDoa2200008. https://doi.org/10.1056/EVIDoa2200008
  2. Sauta, E., Robin, M., Bersanelli, M., Travaglino, E., Meggendorfer, M., Zhao, L. P., Caballero Berrocal, J. C., Sala, C., Maggioni, G., Bernardi, M., Di Grazia, C., Vago, L., Rivoli, G., Borin, L., D'Amico, S., Tentori, C. A., Ubezio, M., Campagna, A., Russo, A., Mannina, D., … Della Porta, M. G. (2023). Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 41(15), 2827–2842. https://doi.org/10.1200/JCO.22.01784
  3. Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Solé, F., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., Kantarjian, H., Kuendgen, A., Levis, A., Malcovati, L., Cazzola, M., Cermak, J., Fonatsch, C., Le Beau, M. M., Slovak, M. L., Krieger, O., … Haase, D. (2012). Revised international prognostic scoring system for myelodysplastic syndromes. Blood, 120(12), 2454–2465. https://doi.org/10.1182/blood-2012-03-420489
  4. Garcia-Manero G. (2023). Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management. American journal of hematology, 98(8), 1307–1325. https://doi.org/10.1002/ajh.26984
  5. Khoury, J. D., Solary, E., Abla, O., Akkari, Y., Alaggio, R., Apperley, J. F., Bejar, R., Berti, E., Busque, L., Chan, J. K. C., Chen, W., Chen, X., Chng, W. J., Choi, J. K., Colmenero, I., Coupland, S. E., Cross, N. C. P., De Jong, D., Elghetany, M. T., Takahashi, E., … Hochhaus, A. (2022). The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia, 36(7), 1703–1719. https://doi.org/10.1038/s41375-022-01613-1
  6. Arber, D. A., Orazi, A., Hasserjian, R. P., Borowitz, M. J., Calvo, K. R., Kvasnicka, H. M., Wang, S. A., Bagg, A., Barbui, T., Branford, S., Bueso-Ramos, C. E., Cortes, J. E., Dal Cin, P., DiNardo, C. D., Dombret, H., Duncavage, E. J., Ebert, B. L., Estey, E. H., Facchetti, F., Foucar, K., … Tefferi, A. (2022). International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood, 140(11), 1200–1228. https://doi.org/10.1182/blood.2022015850
Secret Link